[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fs_xceQ3s9EOjt-YP9EaN6Ctel16M91l8fKKaKz7bAqs":8,"$fQ3weH_2tlxqrxvFEGEIiowjEhej3dz9sRuqtcccMu_o":55,"$fMskWzuPNzXa1gmwiud_eTOo6vLYoPVHYOUwo_ucCiJ8":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},67072,867271,[],"https://ystcdn.venuertc.com/medical/ystApp/1KNmXQDnP2XagGmzBK1qyfRfTWA6Qk1r.png","李浩齐","缙云县新建镇中心卫生院","全科医疗","住院医师",516,0,"肝恶性肿瘤 IV期治疗常用药指南：替雷利珠单抗、仑伐替尼与替吉奥胶囊使用全解","","https://ystcdn.venuertc.com/venue/AI/ac4083bf-80aa-4447-8183-67ca9ee768dc.jpg","\u003Cdiv class=\"material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">肝恶性肿瘤 IV期治疗常用药指南：替雷利珠单抗、仑伐替尼与替吉奥胶囊使用全解\u003C/h1>\n\n  \u003Cdiv class=\"material-intro\">\n    \u003Cp>\n      如果涉及肝脏恶性肿瘤的晚期治疗，替雷利珠单抗、仑伐替尼和替吉奥胶囊这三种药名，你或许已经有所耳闻。这三类药品，包括免疫治疗、靶向药和口服化疗药，在实际治疗中经常搭配使用。其实，药物本身的服用方法、相互作用、不良反应、保存方式等细节，直接决定了治疗效果和安全性。今天，我们打算带你一次性掌握这三种药物的核心用药细节，细致拆解每一个关键环节，让安全用药更轻松、安心。🌱\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 替雷利珠单抗：用药要点 -->\n  \u003Csection class=\"material-section material-bg1\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 替雷利珠单抗：免疫治疗的用药细节\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>剂型与成分说明\u003C/strong>：\u003Cbr>\n        替雷利珠单抗是一种人源化IgG4单克隆抗体，主要以静脉注射剂型存在。每瓶规格为200mg/20ml，需于医院规范条件下由专业人员使用。不建议用于家庭自我操作。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>作用机制\u003C/strong>：\u003Cbr>\n        替雷利珠单抗通过阻断PD-1与其配体结合，减弱癌细胞对免疫系统的“伪装”，让免疫细胞更有效地识别并消灭异常细胞。\u003Cspan aria-label=\"旗帜\">🏳️\u003C/span>（Pardoll, D. M., 2012, Nature Reviews Cancer）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>用法用量\u003C/strong>：\u003Cbr>\n        推荐剂量为200mg，每3周静脉滴注一次。具体给药速度和疗程需严格按照医生指示调整。正确做法：服用前建议抽血检查肝肾功能，滴注过程中注意观察不适反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>药物相互作用\u003C/strong>：\u003Cbr>\n        替雷利珠单抗与其他免疫抑制剂或靶向药物联用时可能增加毒性风险。不应与强效免疫抑制药（如大剂量激素）同时使用，避免影响免疫效力。遇到联合用药，一定让医生知悉所有正在用的药品。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>不良反应及处理\u003C/strong>：\u003Cbr>\n        较常见的副作用有乏力、皮疹、发热和肝酶升高。严重时可能出现免疫相关副作用如肝炎、肺炎等。一旦出现持续高热或明显不适，应立即就医。\u003Cbr>\n        数据：临床显示，约有8-15%的患者会有明显免疫相关反应（Wang et al., 2020, Journal of Hematology & Oncology）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>储存方法\u003C/strong>：\u003Cbr>\n        替雷利珠单抗需冷藏（2-8°C），避免冰冻及阳光直射。药瓶开启后应限制短时间内使用完毕。严禁长期放置常温环境下。（说明书指引）\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特殊人群注意\u003C/strong>：\u003Cbr>\n        老年人和肝功能减退者需评估耐受性。孕妇、哺乳期妇女禁用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>用药案例\u003C/strong>：\u003Cbr>\n        曾有一位60岁男性患者，定期接受200mg替雷利珠单抗，发生轻度消化道不适，经短期对症处理后顺利完成治疗周期。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 仑伐替尼：服用和监测全指南 -->\n  \u003Csection class=\"material-section material-bg2\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 仑伐替尼：靶向药物的服用与监测\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>成分与剂型规格\u003C/strong>：\u003Cbr>\n        仑伐替尼是一种多靶点小分子酪氨酸激酶抑制剂（TKI），口服胶囊制剂，规格常见有4mg、10mg。应整粒吞服，不可嚼碎、压碎或掰开。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>作用机制\u003C/strong>：\u003Cbr>\n        通过抑制肿瘤相关的多种受体（如VEGFR、FGFR等），干预血管生成，从而抑制异常细胞扩增和转移。（Schmidt, C., 2017, Cancer Discovery）\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>最佳服药时间与方法\u003C/strong>：\u003Cbr>\n        仑伐替尼建议每日1次，于同一时段用足量温开水送服，对进餐没有强制要求。但胃部不适者可在餐后半小时服用降低刺激。△建议同一时段用药，便于习惯养成及血药浓度平稳。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>用药剂量调整\u003C/strong>：\u003Cbr>\n        常规起始剂量为8-12mg（按体重区分），具体需遵医嘱调整。若出现明显不良反应，如高血压、蛋白尿，则需减量或暂时停药。正确做法：每周监测血压和尿蛋白。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>服用技巧\u003C/strong>：\u003Cbr>\n        胶囊需整粒吞服，不可掰开。若不慎漏服，不要一次补服两倍剂量，补服方法参考下节。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>药物相互作用\u003C/strong>：\u003Cbr>\n        仑伐替尼与CYP3A4强诱导剂（如利福平）或抑制剂（如酮康唑）联用时，会影响血药浓度，不宜随意合用。服用过程中避免与高脂饮食同时进食。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>监测要求\u003C/strong>：\u003Cbr>\n        建议定期检测肝肾功能和电解质，每1-2周测1次血压。\u003Cspan aria-label=\"显微镜\">🔬\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>常见不良反应及处理\u003C/strong>：\u003Cbr>\n        有25%-40%患者出现食欲下降、疲劳、口腔溃疡或肢体水肿。部分人可出现高血压及蛋白尿，一旦严重须及时就诊。（Kudo, M., et al., 2018, Lancet）\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特殊人群建议\u003C/strong>：\u003Cbr>\n        老年人、肝肾功能异常者用药前须评估。孕妇和哺乳期妇女禁用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>储存模式\u003C/strong>：\u003Cbr>\n        仑伐替尼需置于阴凉干燥处，密封保存，避免与酸性或碱性物质同放。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>漏服和过量处理\u003C/strong>：\u003Cbr>\n        如漏服1次，尽快在当天补服，若已接近下个用药时点，直接跳过，不可叠加服用。若大量误服，需急诊就医。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 替吉奥胶囊：化疗药的精准用法 -->\n  \u003Csection class=\"material-section material-bg3\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 替吉奥胶囊：口服化疗的安全与高效\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>主要成分与剂型\u003C/strong>：\u003Cbr>\n        替吉奥胶囊（S-1）由替加氟、吉美嘧啶和奥替拉西组成。为胶囊口服剂型，常见规格分别为20mg、25mg。每次需足量温水送服，不可嚼碎。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>作用机制\u003C/strong>：\u003Cbr>\n        替吉奥通过抑制DNA合成阻止细胞增殖，辅以代谢抑制剂减少毒副作用，从而提高耐受性。\u003Cspan aria-label=\"药片\">💊\u003C/span>（Shirasaka, T., et al., 1996, Cancer Chemotherapy and Pharmacology）\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>标准用法用量\u003C/strong>：\u003Cbr>\n        通常连续服用28天，停药14天为1周期，需根据体表面积计算剂量（40-60mg/次，早晚各一次）。正确做法：每餐后30分钟内服用，有助于胃肠道吸收且减少刺激感。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>服药技巧与饮食\u003C/strong>：\u003Cbr>\n        建议全程足量水送服，避免空腹服用。服药期间应避免大量摄入含维生素B6的食物，以减轻副作用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>常见不良反应及观察\u003C/strong>：\u003Cbr>\n        8-15%的病人服用过程中可能发生口腔糜烂、腹泻等消化道反应。极个别会有血象异常或皮肤过敏，如白细胞下降或皮疹（Yoshida, K., et al., 2009, Oncology）。\n        正确做法：定期监测血象，出现不适及时与医生沟通。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>药物相互作用\u003C/strong>：\u003Cbr>\n        替吉奥胶囊不宜与嘌呤类代谢抑制剂（如别嘌醇）合用，避免增加毒性反应。服用前需告知医生近期用药情况。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特殊人群注意\u003C/strong>：\u003Cbr>\n        儿童、孕妇和哺乳期妇女严禁使用。70岁以上老年患者应适当减量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>储存方式\u003C/strong>：\u003Cbr>\n        替吉奥需密封保存于25°C以下干燥环境，避免阳光直接照射。过期药物需按照药店回收或医嘱处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>用药案例\u003C/strong>：\u003Cbr>\n        临床报告中有老年患者按照医生建议调整用量后，减轻了腹泻等不良反应，顺利完成周期治疗。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 联合用药与生活管理核心提示 -->\n  \u003Csection class=\"material-section material-bg4\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 联合用药与自我管理注意事项\u003C/h2>\n    \u003Col class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>药物联合风险\u003C/strong>：\u003Cbr>\n        仑伐替尼、替雷利珠单抗和替吉奥胶囊联合使用时，需密切关注毒性叠加风险及血象、肝肾功能变化，务必定期抽血检查。遇到乏力、口腔黏膜炎、持续发热等反应，不可自行停药，需向医生反馈。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>饮食与作息辅助\u003C/strong>：\u003Cbr>\n        治疗期间保持饮食均衡，适量补充蛋白质和维生素，但不要随意服用保健品或中药。足够的休息和规律作息能够辅助药物发挥作用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特殊人群与调整方案\u003C/strong>：\u003Cbr>\n        有严重肝肾功能障碍的患者应严格评估用药风险。孕妇、哺乳期、儿童禁用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>如何安全处理药物\u003C/strong>：\u003Cbr>\n        地面散落药品需戴手套小心收拾，交由药店回收，切忌随意丢弃，避免环境污染和他人误服。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>用药时的常见困惑解答\u003C/strong>：\u003Cbr>\n        1) 出现轻度不良反应是否需立即停药？——建议先沟通医生，判定是否属于药物可耐受范围内。\n        \u003Cbr>\n        2) 怎么判断药物保存是否妥当？——看包装有无受潮、变色或异味，超过有效期坚决不再使用。\n      \u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\n  \u003C!-- 核心回顾与要点总结 -->\n  \u003Csection class=\"material-section material-bg5\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 重点回顾：用药安全的5个关键词\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>剂量严格、定时用药\u003C/strong>：不可随意增减剂量，严格遵医嘱。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>定期监测\u003C/strong>：每2-4周复查肝肾功能、血象、血压。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>出现异常立即咨询\u003C/strong>：如有持续发热、高血压、严重腹泻等症状，立刻就医。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>保存规范\u003C/strong>：低温冷藏（免疫制剂）、密封干燥（口服药物）防变质。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>联合用药风险\u003C/strong>：每增加一种药品，需格外注意相互作用和毒性累加。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-conclusion\">\n      \u003Cp>\n        总之，药物的疗效既依赖科学配伍，也离不开严谨的日常管理。替雷利珠单抗、仑伐替尼及替吉奥胶囊的正确使用，是提高治疗效果和减少风险的基石。牢记剂量、按时服药、关注不良反应，遇到疑问时及时与专业医生沟通，是安全用药的最牢靠保障。🤝\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg6 material-references\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献 \u003Cspan aria-label=\"书\">📚\u003C/span>\u003C/h2>\n    \u003Col class=\"material-ref-list\">\n      \u003Cli>Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. \u003Ci>Nature Reviews Cancer, 12\u003C/i>(4), 252-264.\u003C/li>\n      \u003Cli>Wang, F., et al. (2020). Circulating immune-related adverse events predict efficacy of anti-PD-1 antibodies in advanced cancer. \u003Ci>Journal of Hematology & Oncology, 13\u003C/i>, 95.\u003C/li>\n      \u003Cli>Schmidt, C. (2017). Immunotherapy goes viral. \u003Ci>Cancer Discovery, 7\u003C/i>(8), 789-790.\u003C/li>\n      \u003Cli>Kudo, M., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. \u003Ci>Lancet, 391\u003C/i>(10126), 1163-1173.\u003C/li>\n      \u003Cli>Shirasaka, T., et al. (1996). Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective toxicity of 5-fluorouracil. \u003Ci>Cancer Chemotherapy and Pharmacology, 37\u003C/i>(5): 343-349.\u003C/li>\n      \u003Cli>Yoshida, K., et al. (2009). Prognostic significance of dose intensity of S-1 in the adjuvant setting for advanced cancer: A multicenter clinical trial. \u003Ci>Oncology, 76\u003C/i>(Suppl. 1), 97–104.\u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.material-container {\n  max-width: 900px;\n  margin: 32px auto 40px auto;\n  font-family: \"Segoe UI\", \"PingFang SC\", \"Hiragino Sans GB\", \"Arial\", sans-serif;\n  font-size: 18px;\n  background: #f5f7fa;\n  border-radius: 16px;\n  box-shadow: 0 2px 24px rgba(0,45,120,0.07);\n  padding: 32px 40px 40px 40px;\n  color: #232947;\n  line-height: 1.8;\n  position: relative;\n}\n\n.material-title {\n  font-size: 2.2em;\n  font-weight: 800;\n  margin-bottom: 28px;\n  color: #184e77;\n  text-align: center;\n  border-bottom: 1px solid #b7d5e1;\n  padding-bottom: 9px;\n  letter-spacing: 2px;\n}\n\n.material-intro {\n  padding: 18px 22px;\n  margin-bottom: 24px;\n  background: linear-gradient(90deg, #fceabb 0px, #e4f0fb 100%);\n  border-radius: 10px;\n  font-size: 1.08em;\n  color: #513e25;\n  box-shadow: 0 0 4px rgba(250,200,77,0.06);\n}\n\n.material-section {\n  padding: 38px 22px 32px 22px;\n  margin: 36px 0 20px 0;\n  border-radius: 12px;\n  background-size: cover;\n  background-position: left top;\n}\n\n.material-bg1 {\n  background-image:linear-gradient(120deg,#d6e6fd 60%,#cbe5e3 100%);\n  box-shadow: 0 2px 6px rgba(105,173,207,0.06);\n}\n\n.material-bg2 {\n  background-image: linear-gradient(100deg,#f3e6e8 55%,#fbefff 100%);\n  box-shadow: 0 2px 6px rgba(189,162,184,0.08);\n}\n\n.material-bg3 {\n  background-image: linear-gradient(110deg,#e6f7c5 70%,#cbeef0 100%);\n  box-shadow: 0 2px 6px rgba(161,200,114,0.08);\n}\n\n.material-bg4 {\n  background-image: linear-gradient(120deg,#efd4fb 63%,#f8beec 100%);\n  box-shadow: 0 2px 6px rgba(181,143,194,0.1);\n}\n\n.material-bg5 {\n  background-image: linear-gradient(90deg,#f7e8c7 72%,#dbf7e8 100%);\n  box-shadow: 0 2px 6px rgba(255,202,93,0.09);\n}\n\n.material-bg6 {\n  background: linear-gradient(90deg, #e2fcef 70%, #c7d2fa 100%);\n  box-shadow: 0 2px 8px rgba(85,175,104,0.07);\n}\n\n.material-section h2 {\n  font-size: 1.35em;\n  font-weight: 700;\n  margin-bottom: 22px;\n  color: #346b8d;\n  letter-spacing: 1px;\n  padding-left: 2px;\n  border-left: 5px solid #94c6ee;\n  background-color: rgba(255,255,255,0.18);\n  border-radius: 3px;\n  display: inline-block;\n}\n\n.material-list {\n  margin: 0;\n  padding-left: 24px;\n  font-size: 1.07em;\n  list-style-type: disc;\n  color: #214355;\n}\n\n.material-list li {\n  margin-bottom: 15px;\n  padding-left: 2px;\n  position: relative;\n}\n\n.material-list li strong {\n  color: #0968b9;\n  font-weight: 600;\n}\n\n.material-conclusion {\n  font-size: 1.1em;\n  margin-top: 26px;\n  padding: 15px 17px;\n  background: #f8f5e4;\n  border-radius: 9px;\n  color: #60513e;\n  font-style: normal;\n}\n\n.material-ref-list {\n  margin: 0 0 0 18px;\n  padding: 4px 0;\n  color: #30506a;\n  font-size: 0.98em;\n}\n\n.material-ref-list li {\n  margin-bottom: 7px;\n  padding-left: 2px;\n  line-height: 1.62;\n}\n\n@media (max-width: 990px) {\n  .material-container { padding: 18px 0.5em 22px 0.5em;}\n  .material-title {font-size:1.4em;}\n  .material-section {padding:18px 3vw 18px 3vw;}\n}\n\u003C/style>\n\n","\u003Cdiv class=\"material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color: rgb(",527,"2025-09-23 16:54:13","肝恶性肿瘤, 替雷利珠单抗, 仑伐替尼, 替吉奥胶囊, 免疫治疗, 靶向药物, 口服化疗, 用药指南","了解替雷利珠单抗、仑伐替尼与替吉奥胶囊的用药细节与管理要点，助您安全有效地治疗肝恶性肿瘤 IV期，为患者提供科学的医疗建议。","2025-10-02 22:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]